Stipple Bio, Inc.

1.1 Identity, Stage, and Business Model

Stipple Bio, Inc. is a privately held biotechnology company headquartered in Cambridge, Massachusetts that is building precision-oncology medicines around tumor-specific cell-surface epitopes. The company was founded in 2022 by two academic cancer-biology researchers, Dr. Aaron Ring of the Fred Hutchinson Cancer Center and Dr. Aashish Manglik of the University of California, San Francisco, on the thesis that targeting tumor-specific epitopes (rather than merely tumor-specific gene expression) can widen the therapeutic index of cancer drugs and unlock targets previously considered intractable. Its core asset is the "Pointillist Platform," a modality-agnostic discovery engine that maps tumor-specific epitopes and pairs them with binders designed to avoid on-target/off-tumor toxicity. The lead program, STP-100, is an antibody-drug conjugate (ADC) whose molecular target and indication remain undisclosed. Stipple emerged from stealth only in April 2026, remains pre-clinical, and reports no revenue, no marketed products, and no disclosed customer base. The business model is a classic wholly-owned biotech pipeline play: raise venture capital, advance proprietary assets toward the clinic, and monetize through future partnering, acquisition, or product sales rather than near-term revenue.[CO001, CO002, CO003, CO004, CO005, CO006]

1.2 Founders, Leadership, and Governance

Stipple's identity is anchored in an unusually credentialed scientific founding team paired with a repeat-operator chief executive. Co-founder Aaron Ring is an Associate Professor and Anderson Family Chair for Immunotherapy at Fred Hutch, holds an MD/PhD from Stanford, and has previously founded Simcha Therapeutics, ALX Oncology, and Seranova Bio, giving him a strong founder-market fit and a track record of translating academic immunology into clinical-stage companies. Co-founder Aashish Manglik is an Associate Professor at UCSF specializing in G-protein-coupled receptor structural biology, trained under Nobel laureate Brian Kobilka, a 2026 Vilcek Prize recipient, and co-founder of Epiodyne. Chief Executive Officer Jeff Landau holds an MBA from Stanford Graduate School of Business and was previously a co-founder of Sunterra Bio. Governance is investor-heavy: the board pairs the founders and CEO with general partners and partners from lead investors a16z (Vineeta Agarwala), RA Capital (Derek DiRocco), and Nextech (Thilo Schroeder), plus independent director Owen Hughes and serial biotech founder Gregory Verdine. DiRocco and Schroeder joined the board in conjunction with the Series A. Key-person dependence on Ring's science and Landau's execution is high, and no COO, CFO, or CMO has been publicly named.[CO008, CO009, CO010, CO011, CO012, CO013]

1.3 Funding History, Capital, and Cover Metrics

Stipple has raised across at least three private financings that are corroborated by SEC Form D filings under CIK 0001932776. A 2022 seed round shows a $12.0M offering with $11.975M sold to seven investors (a16z Bio+Health, Emerson Collective, and OMX are named as seed backers), and a December 2024 Form D shows a $15.0M offering with $9.476M sold, implying roughly $21.5M of pre-Series A capital. In April 2026 the company announced a $100M "heavily oversubscribed" Series A co-led by RA Capital, a16z Bio+Health, and Nextech Invest, with participation from Emerson Collective (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners, and GordonMD Global Investments; proceeds are said to fund the company into 2029. The corresponding Form D, filed April 6, 2026, reports a $100.2M total offering but only $65.13M sold as of filing with $35.07M remaining across 15 investors, a material nuance for diligence because the public "$100M closed" framing exceeds the amount the filing shows sold. Cover metrics such as valuation, revenue run-rate, customer count, and headcount are not disclosed; a widely referenced $2.25B unicorn valuation is not supported because Stipple does not appear on the July 2026 TechCrunch unicorn list, so those metrics are recorded here as null with explicit diligence paths.[CO016, CO017, CO018, CO019, CO020, CO021]

1.4 Milestones, Partnerships, and Adverse Checks

Stipple's short public history is a compact chronology of financings, a platform reveal, and one commercial partnership. The company incorporated and seeded in 2022, added capital in late 2024, emerged from stealth alongside its $100M Series A on April 6, 2026, and in June 2026 signed a multi-target ADC licensing agreement with contract development and manufacturing organization Lonza, gaining target-specific access to Lonza's GlycoConnect, HydraSpace, and toxSYN (Synaffix-derived) site-specific ADC toolkit for programs including STP-100. Adverse and conflicting signals are modest but real: the target and indication for STP-100 are undisclosed, no human data exist, the IND is only guided for early 2027, and no ClinicalTrials.gov study is yet registered. Financially, the Series A Form D shows less capital sold ($65.1M) than the announced $100M close, and the promoted $2.25B valuation is unverified. No litigation, recalls, layoffs, sanctions, or leadership departures were found in public sources as of the run date, which is consistent with an early, recently unstealthed company but also reflects thin public disclosure rather than a clean, deeply documented record.[CO025, CO026, CO027, CO028, CO029, CO030]

1.5 Exhibits

2.1 Market Boundary and Substitutes

Stipple Bio's relevant market is the antibody-drug conjugate (ADC) segment of oncology therapeutics, itself a slice of the broader precision-oncology market for targeted cancer medicines. Included spend is revenue from ADC products sold to treat solid and hematologic tumors, plus, more loosely, the targeted-therapy budget that epitope-selective ADCs could capture. Adjacent but excluded categories are immune-checkpoint inhibitors, CAR-T and cell therapies, bispecific antibodies, small-molecule targeted drugs, and molecular diagnostics; these are substitutes or complements rather than the ADC category itself. The status-quo alternatives a new ADC must displace are existing approved ADCs such as Enhertu (trastuzumab deruxtecan), Trodelvy, and Elahere, conventional cytotoxic chemotherapy, and targeted small molecules. Stipple's specific wedge is narrower still: ADCs aimed at tumor-specific epitopes on targets that have been clinically validated but limited by on-target/off-tumor toxicity. That framing makes the true addressable market a function of how many such toxicity-constrained targets exist and can be "unlocked," which is not publicly quantified and is treated here as an evidence-constrained boundary rather than a clean TAM.[CM001, CM002, CM003, CM004, CM005, CM031]

2.2 Market Sizing Across Multiple Lenses

No single number captures Stipple's opportunity, so this analysis stacks several lenses. At the broadest layer, global cancer incidence was roughly 20 million new cases in 2022 and is projected to rise toward 35 million by 2050, with about 2.1 million new US cases estimated for 2026, underpinning durable demand. The precision-oncology market that Stipple ultimately sells into is estimated at roughly $128-146 billion in 2026, growing at high-single to low-double-digit rates toward $300-339 billion by the mid-2030s. The ADC segment specifically is estimated at about $16.7 billion (Grand View) to $22.6 billion (Fortune Business Insights) in 2026, with forecasts to $32-68 billion by 2033-2034 at CAGRs of roughly 11.5-15%; other trackers put ADC sales past $16 billion in 2025 and above $46 billion by 2030. These estimates disagree by wide margins because of differing definitions, geographies, and base years, so they are preserved as a range rather than reconciled to one figure. The serviceable and obtainable layers collapse sharply for Stipple: as a single-asset pre-clinical company it has no revenue, and any obtainable share is a risk-adjusted fraction of one future ADC's peak sales, which cannot be sized credibly until the STP-100 target and indication are disclosed.[CM006, CM007, CM008, CM009, CM010, CM011]

2.3 Buyers, Payers, and the Adoption Path

For a pre-clinical platform biotech, "buyers" exist on two horizons. Near term, Stipple's effective customers are capital providers and potential pharma licensees: venture investors fund the pipeline, and large pharmaceutical companies are the acquirers or partners who ultimately pay for validated ADC assets, as evidenced by the ADC deal wave and Stipple's own CDMO relationship with Lonza. Long term, once (if) STP-100 reaches market, the end-market buyer structure is the standard oncology chain: oncologists and hospital pharmacies select and administer the drug, patients receive it, and payers (commercial insurers, pharmacy benefit managers, and government programs such as Medicare) own the budget and gate reimbursement. The adoption trigger is a sequence: FDA approval, inclusion in NCCN/clinical guidelines, payer coverage decisions, and demonstrated therapeutic-index advantage over incumbent ADCs and chemotherapy. Because ADCs are premium-priced specialty products, payer scrutiny of incremental benefit versus cost is a real adoption filter, and a differentiated safety profile (Stipple's core claim) is exactly the attribute that can justify premium positioning if it survives clinical testing.[CM014, CM015, CM016, CM017, CM018, CM019]

2.4 Growth Drivers and Adoption Constraints

The tailwinds behind ADCs are substantial. Clinical validation and label expansion (led by Enhertu, which posted roughly $4.4-5 billion in 2025 sales) have made ADCs a core oncology pillar; big-pharma M&A has repeatedly paid up for the modality (Pfizer-Seagen at $43B, AbbVie-ImmunoGen at $10.1B, and J&J's ~$1B purchase of pre-clinical Firefly Bio); linker and payload chemistry keep improving; and there is genuine unmet need on targets that current drugs cannot exploit without unacceptable toxicity, which is precisely Stipple's thesis. Offsetting constraints are equally real. The field is crowded, with roughly 2,800 ADC candidates in development and 23 approved products, so differentiation is hard. ADCs carry recognized safety liabilities, most notably interstitial lung disease and pneumonitis with black-box warnings on leading agents, which raises the clinical and regulatory bar. Manufacturing and CMC are complex and capital-intensive, reinforcing dependence on partners like Lonza. And demand is not guaranteed to compound smoothly: Daiichi Sankyo took an $850 million charge and cut ADC facility investment as it trimmed demand forecasts, a caution flag for the whole segment. These countervailing forces are preserved rather than netted to a single verdict.[CM021, CM022, CM023, CM024, CM025, CM026]

2.5 Exhibits

3.1 The Competitive Landscape

Stipple sits inside one of oncology's most contested arenas. The landscape spans five tiers. Direct peers are other next-generation ADC/conjugate platform companies pursuing better therapeutic index, most notably Firefly Bio (a degrader-antibody-conjugate platform acquired by Johnson & Johnson for about $1 billion upfront in June 2026) and European players such as Tubulis and Adcendo. Incumbents are the commercial ADC leaders: Daiichi Sankyo and AstraZeneca (Enhertu, the category's ~$4-5 billion flagship, plus the newly approved TROP2 agent Datroway), Gilead (Trodelvy), AbbVie (Elahere via the $10.1B ImmunoGen deal), and Pfizer (the $43B Seagen franchise of Adcetris, Padcev, Tivdak, and Tukysa). Adjacent modalities that compete for the same treatment slots include immune-checkpoint inhibitors, bispecific antibodies, and CAR-T. Substitutes and status-quo care are conventional chemotherapy and targeted small molecules. Finally, the most strategically important "competitor" may be internal build: every large ADC incumbent operates its own discovery and conjugation platform, and China-based developers are entering rapidly. With roughly 2,800 ADC candidates in development and 23 approved products, the field is dense, and Stipple must prove that epitope-level selectivity is a durable edge rather than a marginal one.[CP001, CP002, CP003, CP004, CP005, CP006]

3.2 Competitor Profiles and Scale

The incumbents dwarf Stipple on every measurable axis. Daiichi Sankyo/AstraZeneca anchor the category with Enhertu, whose 2025 sales approached $4.4-5 billion and whose TROP2 follow-on Datroway won a first-line metastatic triple-negative breast cancer approval in May 2026 with the first statistically significant overall-survival benefit for a TROP2 ADC (median OS 23.7 months versus 18.7). Gilead's Trodelvy secured a broad first-line mTNBC approval in June 2026 and had treated roughly 75,000 patients by mid-2026, giving it entrenched physician familiarity. AbbVie's Elahere (folate-receptor-alpha ovarian cancer) and Pfizer's four-product Seagen franchise round out the commercial leaders. Against these, Stipple is a single-asset, pre-clinical company with a $100M Series A and one undisclosed-target program, STP-100. Its most comparable peer is Firefly Bio, which was also pre-clinical yet commanded a ~$1B acquisition on the strength of a novel conjugate platform for KRAS-driven tumors, a useful benchmark for how the market values differentiated ADC-adjacent platforms before clinical data. Emerging platform peers (Tubulis, Adcendo, Ona Therapeutics, and Merck-Kelun's sacituzumab tirumotecan) show the segment is filling quickly with credible science.[CP008, CP009, CP010, CP011, CP012, CP013]

3.3 Capability, Pricing, and Positioning

On capability, Stipple's proposition is narrow but sharp: identify tumor-specific epitopes so an ADC can hit a target that incumbents cannot exploit without dose-limiting toxicity. That is a differentiation claim on the discovery front-end, whereas the incumbents differentiate on validated payload-linker chemistry, breadth of approved indications, and distribution. On pricing, no comparison is yet possible for Stipple because it has no product; incumbent ADCs are premium-priced specialty biologics whose costs frequently exceed common US cost-effectiveness thresholds, so any Stipple entrant would face the same payer scrutiny. On go-to-market and regulatory posture, incumbents hold decisive advantages: approved labels, established safety databases, and manufacturing scale, while Stipple depends on a Lonza license for conjugation technology and has no clinical or regulatory track record of its own. The positioning map that follows places Stipple in the high-differentiation, low-maturity quadrant alongside Firefly and Tubulis, distinct from the high-maturity incumbents but exposed to the risk that maturity, not novelty, is what wins share and reimbursement.[CP016, CP017, CP018, CP019, CP020, CP021]

3.4 Switching Costs, Moat Durability, and Adverse Evidence

In therapeutics, "switching cost" is really clinical evidence and guideline entrenchment: once an ADC is standard of care with a mature safety profile, displacing it requires superior randomized data, which takes years and hundreds of millions of dollars. That dynamic favors incumbents like Trodelvy and Enhertu and works against a pre-clinical entrant. Stipple's potential moat is its platform IP and the quality of the epitopes it discovers, reinforced by the Lonza conjugation partnership. But durability is questionable on several fronts. First, every major incumbent has an internal ADC platform, so Stipple's discovery edge could be replicated or out-resourced. Second, the ADC IP landscape is turbulent: in December 2025 the Federal Circuit invalidated Seagen's foundational '039 linker patent for lack of written description and enablement, a ruling that both eases freedom-to-operate and signals how contestable ADC patents are. Third, adverse segment-level evidence is mounting: Daiichi took an $850M charge and cut ADC facility investment as it trimmed demand forecasts. Net, Stipple's moat is a plausible but entirely unproven discovery advantage sitting inside a fast-commoditizing, litigation-prone, capital-heavy category.[CP023, CP024, CP025, CP026, CP027, CP028]

3.5 Exhibits

4.1 Revenue Model and Monetization

Stipple has no current revenue. As a pre-clinical drug developer it recognizes no product sales, no service revenue, and no recurring income, and none of the usual SaaS-style metrics (ARR, GMV, active users) apply. Its revenue model is prospective and two-pronged. The primary path is a wholly-owned pipeline: advance STP-100 and follow-on ADCs through the clinic and monetize via product sales, out-licensing, or acquisition, mirroring how peers like Firefly Bio realized value through a ~$1B buyout while still pre-clinical. A secondary, optional path is platform licensing, in which Stipple could grant pharma partners access to Pointillist-discovered epitopes for upfront, milestone, and royalty payments; management has said biopharma companies have approached it, though it has signalled a preference for wholly-owned assets. Notably, Stipple currently sits on the paying side of a comparable structure: under its Lonza license it owes upfront, milestone, and royalty consideration for conjugation technology. Until a clinical asset or a signed platform deal exists, revenue quality cannot be assessed and every revenue line is recorded as null with a diligence path.[CI001, CI002, CI003, CI004, CI005, CI020]

4.2 Cost Structure and Unit Economics

Because there is no product, Stipple has no cost of goods sold, no gross margin, and no customer-acquisition economics; conventional unit-economics analysis is not yet meaningful. The cost base is dominated by research and development — epitope discovery, antibody engineering, payload/linker work, and IND-enabling studies — plus general and administrative expense for a lean, largely undisclosed headcount. The go-to-market "motion" is effectively a capital-efficiency question: how much cash is required to reach the next value-inflection milestone (IND filing and first-in-human data guided for early 2027). Manufacturing is capital-light on paper because Stipple outsources conjugation and manufacturing to Lonza, but that outsourcing converts fixed capex into variable milestone and royalty obligations, and ADC CMC is notoriously complex and expensive. The only defensible "unit" lens today is cost-per-milestone: the Series A is explicitly sized to fund the company into 2029 and through multiple early-stage studies, implying a multi-year, tens-of-millions-per-year burn profile, but the actual figures are not disclosed and are treated as estimates or gaps rather than facts.[CI006, CI007, CI008, CI009, CI010, CI021]

4.3 Capital Adequacy, Burn, and Runway

Capital adequacy is the crux of Stipple's financial profile, and here SEC Form D filings provide hard anchors even though the company is private. A 2022 seed Form D reports a $12.0M offering with $11.975M sold to seven investors; a December 2024 Form D reports a $15.0M offering with $9.476M sold; and the April 2026 Series A Form D reports a $100.2M offering with $65.13M sold and $35.07M remaining across 15 investors. Summing the amounts actually sold implies roughly $21.5M raised before the Series A and about $86.6M sold across all filings to date, versus the promoted "$100M closed" headline. Management guides that the Series A funds the company into 2029, which — if the full $100M is ultimately collected — implies an average burn on the order of $30-35M per year over roughly three years; if only the $65.13M sold is available, the runway math tightens materially. Cash on hand, exact monthly burn, the valuation, and a line-item use of funds are all undisclosed. The next financing trigger is clinical progress: an IND and early human data would support a Series B step-up, consistent with a 2026 environment where oncology Series B rounds commonly run $150-250M. Financing dependency is therefore high and milestone-contingent.[CI011, CI012, CI013, CI014, CI015, CI016]

4.4 Financial Verdict and Diligence Blockers

The financial verdict is that Stipple cannot be underwritten on fundamentals today because the fundamentals do not yet exist: there is no revenue to judge for quality, no margin path to model, and no unit economics to stress. What can be judged is capital posture, and it is a mixed picture. On the positive side, the company is well-capitalized for its stage relative to 2026 benchmarks (biotech Series A rounds averaged roughly $75-100M pre-money in oncology), has blue-chip investors, and has outsourced the most capital-intensive manufacturing steps to Lonza. On the cautious side, the gap between the announced $100M and the $65.13M shown sold on the Form D, the undisclosed cash and burn, the undisclosed valuation, and a multi-year path to any revenue make this a financing-dependent, binary asset. The primary diligence blockers are: obtain audited cash and monthly burn, reconcile the announced-versus-sold Series A amount, get a line-item use of funds, and quantify the Lonza economic obligations. Until those are answered, the financial profile is "adequately funded to the next milestone, but opaque and financing-dependent beyond it."[CI016, CI017, CI018, CI019, CI025, CI026]

4.5 Exhibits

5.1 What Stipple Delivers

In customer-workflow terms, Stipple delivers two connected things: a discovery capability and the drug candidates that come out of it. The discovery capability is the Pointillist Platform, a modality-agnostic system that identifies tumor-specific cell-surface epitopes — the precise sub-regions of an antigen that an antibody's paratope or a T-cell receptor binds. The insight is that a target can be expressed on both tumor and healthy tissue, but the epitope landscape differs; by finding epitopes that are accessible on cancer cells yet hidden or absent on normal cells, Stipple aims to hit validated-but-toxic targets without the on-target/off-tumor toxicity that has limited prior drugs. The output for a drug developer (whether Stipple itself or a future partner) is a differentiated binder plus a target hypothesis that widens the therapeutic index. The lead product of that engine is STP-100, an antibody-drug conjugate whose binder is designed to discriminate tumor epitopes and whose payload is delivered via Lonza's conjugation chemistry. As of the run date, STP-100 is pre-clinical, with clinical entry guided for early 2027, so the "product" is best understood as a platform plus one lead asset rather than a marketed therapy.[CE001, CE002, CE003, CE004, CE005, CE006]

5.2 Technology and Operating Architecture

Stipple's operating model is a pre-clinical ADC value chain layered on top of a proprietary discovery front-end. The stack begins with epitope discovery (the Pointillist Platform), rooted in the founders' academic methods: Aaron Ring's protein-engineering and systems-immunology work (including the REAP antigen-discovery platform) and Aashish Manglik's structural biology of membrane proteins and receptors. The next layer is binder generation — antibodies engineered to recognize the selected tumor epitope. The third layer is conjugation, where Stipple licenses Lonza's site-specific GlycoConnect technology (which uses antibody glycans to attach payloads for a homogeneous drug-to-antibody ratio), the HydraSpace polar spacer (for stability and solubility), and the toxSYN linker-payload. The fourth and fifth layers are pre-clinical validation (internalization, normal-tissue cross-reactivity, PK, tolerability) and CMC/manufacturing, both of which lean heavily on Lonza. The final layer is clinical execution, not yet begun. This architecture concentrates Stipple's proprietary value in the discovery and binder-selection layers while outsourcing the chemistry and manufacturing that ADC programs most often stumble on.[CE007, CE008, CE009, CE010, CE011, CE012]

5.3 Maturity, Differentiation, and IP

Technically, Stipple is early. The Pointillist Platform and STP-100 were disclosed only in April 2026, there is no peer-reviewed publication describing Pointillist itself, no human data exist, and no ClinicalTrials.gov study is registered. Maturity therefore rests on inference from the founders' published science rather than on platform-specific validation. Differentiation is real but narrow: the claimed edge is epitope-level selectivity at the discovery front-end, which — if it holds up — lets Stipple pursue targets that incumbents cannot exploit safely. That is a data/know-how moat more than a chemistry moat, since the conjugation chemistry is licensed from Lonza and therefore in principle available to others. Intellectual property around the platform and specific epitopes is presumably the core defensible asset, but no patents are publicly detailed, and the broader ADC IP environment is contested (a 2025 Federal Circuit ruling invalidated a foundational linker patent). The most credible near-term technical proof points would be a peer-reviewed Pointillist dataset, pre-clinical tumor-versus-normal selectivity data for STP-100, and a disclosed, defensible target — none of which is yet public.[CE014, CE015, CE016, CE017, CE018, CE019]

5.4 Trust, Safety, Quality, and Compliance

For an ADC, trust and quality are dominated by safety and manufacturing control. The entire Stipple thesis is a safety argument: epitope selectivity is meant to reduce on-target/off-tumor toxicity, the class liability that produces dose-limiting effects and, for several marketed ADCs, black-box warnings for interstitial lung disease and pneumonitis. Quality on the chemistry side depends on Lonza's platforms: GlycoConnect's site-specific conjugation is designed to yield a homogeneous, well-characterized drug-to-antibody ratio, which matters for reproducibility, safety, and regulatory review. On the regulatory-quality front, any STP-100 program must satisfy modern FDA expectations, including the 2024 clinical-pharmacology guidance for ADCs and the Project Optimus dose-optimization initiative, which pushes sponsors toward randomized dose-finding rather than maximum-tolerated-dose designs. Stipple has no GMP or clinical-quality track record of its own and relies on Lonza for manufacturing controls, so quality assurance is partly a partner-diligence question. The central unresolved safety question is empirical: whether epitope selectivity actually translates into a cleaner normal-tissue profile in vivo, which only pre-clinical and clinical data can answer.[CE021, CE022, CE023, CE024, CE025, CE026]

5.5 Exhibits

6.1 Who Pays and Who Uses

Stipple's customer structure must be described on two horizons because it has no current buyers. Near term, the relevant "customers" are capital markets and prospective pharma partners: venture investors fund the company, and large pharmaceutical companies are the entities that would license the platform or acquire assets, as the broader 2026 deal environment (over $250B of biopharma licensing in 2025, with oncology and next-generation antibodies the dominant segment) makes clear. Stipple's CEO has said biopharma companies have approached the company to collaborate via the Pointillist Platform, though management has signalled a preference for wholly-owned assets. The one concrete commercial relationship today inverts the usual direction: under the Lonza license, Stipple is the customer, paying for conjugation technology and manufacturing. Long term, once (if) STP-100 is approved, the end-market customer chain is the standard oncology structure — oncologists and hospital pharmacies select and administer the drug, patients receive it, and payers own the budget and gate reimbursement. No customer can be segmented by revenue band, vertical, or geography yet because none exists; the segmentation below is therefore of prospective and proxy customers.[CU001, CU002, CU003, CU004, CU005, CU006]

6.2 Adoption Trajectory and Demand Signals

There is no product adoption trajectory to measure — no active users, accounts, deployments, or utilization — so the evidence here is category adoption and platform demand, used as leading indicators rather than proof. At the category level, ADCs are now mainstream in solid-tumor oncology, with more than 15 approved products, worldwide ADC sales exceeding $16 billion in 2026, and rapid uptake in breast, lung, urothelial, and ovarian cancers; this validates the end-market Stipple is aiming at even though it says nothing about STP-100 specifically. At the platform level, pharma demand for antibody-discovery and next-generation oncology platforms is unusually strong in 2026 (record licensing values, deals such as BMS-BioNTech and AbbVie-RemeGen), which is the demand pool Stipple's optional licensing model would tap. The most concrete Stipple-specific demand signal is the June 2026 Lonza agreement plus reported inbound interest from biopharma companies. These are genuine but soft signals: they show the market is receptive to differentiated ADC platforms, not that anyone has yet committed to Stipple's science.[CU007, CU008, CU009, CU010, CU011, CU012]

6.3 Named Customer Proof (and Its Absence)

Honest diligence must state plainly that Stipple has no named production customers, no pilots, and no reference accounts, because it has no product to deploy. The closest analogues to "named customer proof" are: Lonza, a signed commercial counterparty (with Stipple as the paying customer rather than the vendor); unnamed biopharma companies that have reportedly approached Stipple about platform collaboration; and the investor syndicate, whose capital is a proxy vote of confidence but not customer demand. None of these is a customer buying Stipple's output, so the named-customer table below is explicitly a sample of proxy relationships with an open evidence gap, not an exhaustive customer roster. The quality of this "proof" is low on the conventional scale — it is demand-side interest and a supplier contract, not revenue or usage — and its freshness is current (April-June 2026). The single most valuable future proof point would be a signed platform collaboration or partnership with a named pharma company on disclosed economics.[CU014, CU015, CU016, CU017, CU018, CU032]

6.4 Retention, Expansion, and Concentration Risk

Retention metrics — net revenue retention, gross retention, churn, renewal, cohort behavior — do not exist because there are no customers or contracts to retain, so every such metric is recorded as null with a diligence path. What can be assessed is concentration and dependency risk, and here the picture is stark. Stipple's "revenue" future is concentrated in a single pre-clinical asset (STP-100) against an undisclosed target, so program risk is effectively customer-concentration risk by another name: if that program fails, there is no diversified customer base to fall back on. Supply-and-partner concentration is also high: Lonza is the sole disclosed conjugation and manufacturing partner, creating a single point of dependency for the chemistry that any future customer relationship relies on. On expansion, the bullish case is land-and-expand at the platform level — one pharma collaboration validating the science could seed multiple target-by-target deals — but that is entirely prospective. Procurement friction for the eventual end-market (payer cost-effectiveness scrutiny, where many ADCs exceed common $/QALY thresholds) is a further adoption filter years away. Net, concentration risk is high and durability is unproven.[CU019, CU020, CU021, CU022, CU023, CU024]

6.5 Exhibits

7.1 Severity-Ranked Risk Overview

Stipple's risk profile is that of a single-asset, pre-clinical oncology company: concentrated, binary, and front-loaded with scientific uncertainty. Ranked by severity, the top risks are (1) clinical/technical failure — oncology programs have only a roughly 5-7% likelihood of approval from Phase 1, and Phase 2 is the historical "valley of death"; (2) safety — ADCs carry recognized interstitial lung disease and pneumonitis risks that have produced black-box warnings and at least one FDA clinical hold after fatal events, and Stipple's whole thesis is an unproven safety claim; (3) target risk — STP-100's target is undisclosed and unvalidated, so its druggability and competitive freedom are unknown; (4) IP/legal — ADC patents are contested, as shown by the 2025 Federal Circuit invalidation of a foundational linker patent; (5) dependency — reliance on Lonza for chemistry/manufacturing and on capital markets for financing; and (6) financial — high burn, an undisclosed valuation, and a gap between the announced $100M and the $65.1M sold on the Form D. Mitigation maturity is low across the board because no human data exist; residual exposure is therefore high, and this is an asset whose value is dominated by low-probability, high-payoff binary outcomes.[CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Regulatory and Legal Risk

Regulatory risk begins with the sheer distance to market: STP-100's IND is only guided for early 2027, no trial is registered on ClinicalTrials.gov, and any program must satisfy modern FDA expectations, including the 2024 clinical-pharmacology guidance for ADCs and the Project Optimus dose-optimization mandate that pushes sponsors toward randomized dose-finding rather than maximum-tolerated-dose designs. Safety-driven regulatory action is a live precedent: the FDA placed a clinical hold on a Merck-Daiichi ADC after fatal lung-toxicity events, illustrating how quickly an ADC program can be halted. Legal and intellectual-property risk is equally material. The ADC IP landscape is turbulent — in December 2025 the Federal Circuit invalidated Seagen's foundational '039 linker patent for lack of written description and enablement — which cuts both ways: it can ease freedom-to-operate but also shows that ADC patents (potentially including Stipple's own future IP) are vulnerable. Because Stipple licenses its conjugation chemistry from Lonza and targets an undisclosed, possibly IP-encumbered target, its freedom-to-operate cannot be verified from public information, and no patent estate for the platform is publicly detailed.[CR008, CR009, CR010, CR011, CR012, CR013]

7.3 Operational, Quality, and Safety Risk

Operationally, ADCs are among the hardest biologics to manufacture, and Stipple has no in-house chemistry, manufacturing, and controls (CMC) capability, relying instead on Lonza's GlycoConnect, HydraSpace, and toxSYN platforms. That outsourcing mitigates capex but concentrates manufacturing-quality risk in a single partner and leaves Stipple without its own GMP track record. The dominant quality risk is safety. Class-level data show pneumonitis in roughly 4.4% of ADC recipients (about 2.35% grade 3 or worse) and interstitial lung disease around 11.4% for trastuzumab deruxtecan, with fatal cases documented and black-box warnings on leading agents; drug- to-antibody ratio consistency, linker stability, and payload potency all bear on this profile. Stipple's mitigation is design-level — epitope selectivity and GlycoConnect's homogeneous DAR are meant to reduce off-tumor toxicity — but none of this is yet demonstrated in vivo. Recalls, outages, and facility risk are not applicable at this stage, but scale-up, comparability, and supply reliability will become acute as the program approaches the clinic.[CR016, CR017, CR018, CR019, CR020, CR021]

7.4 Partner, Dependency, and Financial Risk

Dependency risk is concentrated on three counterparties: Lonza (the sole disclosed chemistry and manufacturing partner, whose license terms and exclusivity are undisclosed), the investor syndicate (Stipple is financing-dependent and must raise again on clinical milestones), and the founders and lean executive team (key-person risk, with no publicly named CFO, COO, or CMO). Because Stipple has no customers, "customer concentration" manifests as single-asset concentration: STP-100 is the whole near-term thesis. Financial and model risk is significant. Burn is undisclosed but implied at roughly $30-35M per year, the Series A Form D shows $65.1M sold against a $100M announced round with $35M still to be collected, the post-money valuation is undisclosed, and the company is on a multi-year path to any revenue with a ~5-7% probability of the lead program reaching approval. Sector-level financial signals are also cautionary: Daiichi Sankyo took an $850M charge and cut ADC facility investment as demand forecasts fell, and many marketed ADCs already exceed common cost-effectiveness thresholds, foreshadowing eventual pricing and reimbursement pressure.[CR024, CR025, CR026, CR027, CR028, CR029]

7.5 Mitigations, Monitoring, and Kill Criteria

Mitigation maturity is low but not zero. Scientifically, the founders' pedigree and the design-level safety rationale (epitope selectivity, homogeneous DAR via GlycoConnect) partially de-risk the thesis, and the Lonza partnership de-risks chemistry execution. Capital is adequate to the next milestone. The key monitoring indicators an investor should track are: disclosure of the STP-100 target and pre-clinical tumor-versus-normal selectivity data; IND acceptance and first-in-human dosing; any FDA safety signal or hold; reconciliation of the announced-versus-sold Series A amount; and evidence of freedom-to-operate. Thesis-break (kill) triggers include: pre-clinical data showing no meaningful selectivity advantage; an IND clinical hold or serious/fatal lung toxicity in early dosing; discovery that the target is already IP-blocked or clinically de-risked by a competitor; a failure to raise the Series B on milestone terms; or a material change in the Lonza relationship. The diligence asks that would most reduce uncertainty are the pre-clinical data package, the target identity under NDA, the Lonza license terms, audited cash and burn, and a patent/FTO opinion.[CR033, CR034, CR035, CR036, CR037, CR038]

7.6 Exhibits

8.1 Thesis and Anti-Thesis

The investment thesis for Stipple is that a credentialed founding team has built a genuinely differentiated discovery platform — epitope-level targeting that could unlock validated-but-toxic cancer targets — inside a large and richly funded ADC/precision-oncology market, with a blue-chip syndicate, a de-risking Lonza chemistry partnership, and capital that funds the company into 2029. The market's willingness to pay for differentiated conjugate platforms is demonstrated by J&J's ~$1B acquisition of pre-clinical Firefly Bio and by record 2026 biopharma licensing. The anti-thesis is that none of this is yet proven: Stipple is a single-asset, pre-clinical company against an undisclosed and unvalidated target, oncology programs have only a ~5-7% likelihood of approval from Phase 1, ADCs carry class-level safety liabilities that have triggered FDA holds, ADC IP is contestable, the field is crowded, and even the headline capital is softer than advertised ($65.1M sold on the Form D versus the announced $100M). Critically, there is no confirmed valuation to test against this evidence, so entry discipline cannot be exercised on price today.[CV001, CV002, CV003, CV004, CV005, CV006]

8.2 Recommendation, Confidence, and Risk Rating

The recommendation is research-more. Stipple is a scientifically interesting, well-sponsored company, but the specific inputs needed to underwrite a price — the STP-100 target, pre-clinical selectivity data, the post-money valuation, and the Lonza economics — are all undisclosed, so a buy/track call would be speculation rather than analysis. Confidence in any point estimate is low given the pre-clinical stage and information gaps, and the risk rating is high: this is a binary asset whose outcome distribution is dominated by low-probability, high-payoff clinical events. The appropriate posture for a prospective investor is to treat the round as an option on platform validation and to condition participation on obtaining the missing disclosures under NDA. For an existing holder, the milestone path (IND and first human data, guided for early 2027) is the value driver to monitor. Valuation stance is unknown because no valuation is confirmed; if the circulated $2.25B figure were accurate, it would look stretched-to-expensive for a single pre-clinical asset, but that figure is unverified and should not anchor the analysis.[CV008, CV009, CV010, CV011, CV012, CV013]

8.3 Financing Context, Entry Discipline, and Price Support

The financing context is a $100M Series A announced in April 2026, co-led by RA Capital, a16z Bio+Health, and Nextech, on top of roughly $21.5M of pre-Series A capital. The corresponding SEC Form D reports a $100.2M offering with $65.1M sold and $35.1M still to be collected, which both confirms the round's scale and flags that the fully-funded headline is not yet complete. No post-money valuation is disclosed anywhere in company or filing sources, and Stipple does not appear on the July 2026 TechCrunch unicorn list, so the widely circulated $2.25B valuation is not supported by any authoritative source and is treated here as unverified. Because price is unknown, standard entry-discipline tests (multiple of invested capital, implied step-up, preference overhang) cannot be run; a prospective investor should assume a standard venture liquidation-preference stack (about 1x non-participating) until term-sheet detail is available. The honest conclusion is that public evidence does not currently support any specific price — it supports the existence of a large, credible round, not a defensible valuation.[CV014, CV015, CV016, CV017, CV018, CV019]

8.4 Bull, Base, and Bear Scenarios

Scenario analysis, not a point estimate, is the right lens for a pre-clinical asset. In the bull case, the Pointillist Platform validates, STP-100 shows a clean tumor-versus-normal selectivity window, the IND proceeds on time, and a pharma partnership or acquisition follows; comparable outcomes range from Firefly's ~$1B pre-clinical exit to ImmunoGen's $10.1B commercial-stage acquisition, implying a multi-billion-dollar upside if the science and a lead indication mature. In the base case, Stipple reaches the clinic with partial validation and raises a Series B at a modest step-up (2026 oncology Series B rounds commonly run $150-250M), keeping the option alive without a definitive outcome. In the bear case — the statistically most likely single path given a ~5-7% approval rate — pre-clinical or early-clinical data disappoint, a safety signal or clinical hold emerges, the target proves de-risked or IP-blocked, or the Series B fails, driving value toward residual cash. The wide dispersion between these outcomes, and the fact that the bear case carries the highest single-path probability, is the defining feature of the valuation.[CV020, CV021, CV022, CV023, CV024, CV025]

8.5 Comparable Set

Because Stipple has no revenue, comparables are transaction-based rather than multiple-based. The most directly relevant comp is Firefly Bio, a pre-clinical conjugate-platform company acquired by J&J for about $1 billion upfront in June 2026 — evidence that the market will pay nine figures for a differentiated, still-pre-clinical ADC-adjacent platform. Commercial-stage ADC M&A sets the upper bound: AbbVie bought ImmunoGen for $10.1B (for the approved Elahere) and Pfizer bought Seagen for $43B (a four-product franchise). Antibody-platform partnering comps (BMS-BioNTech at $11.1B, AbbVie-RemeGen at $5.6B) and the broader 2026 licensing market (over $250B in 2025, average deal ~$1.3B) show deep strategic demand. On the private side, 2026 oncology Series A rounds averaged roughly $75-100M pre-money, so Stipple's $100M raise is large-but-consistent for a marquee team. These comps bound the outcome space but do not price Stipple, because every high comparable reflects either clinical/commercial de-risking or a disclosed platform Stipple has not yet matched.[CV027, CV028, CV029, CV030, CV031, CV032]

8.6 Exit Readiness and Final Diligence

Exit readiness favors M&A. ADC and conjugate platforms have been serial acquisition targets (Seagen, ImmunoGen, Firefly), and Stipple's wholly-owned, single-asset structure is well-suited to a trade sale if STP-100 de-risks; an IPO is possible but would require clinical data and a more built-out pipeline. The final diligence asks that would most change the valuation are: the STP-100 target identity and pre-clinical selectivity/tox data; the post-money valuation, cap table, and preference stack; audited cash and monthly burn; the Lonza license economics and exclusivity; and a freedom-to-operate/patent opinion. The thesis-break triggers that would move the recommendation from research-more to avoid are a pre-clinical failure to show selectivity advantage, a serious safety signal or clinical hold, discovery that the target is IP-blocked or already de-risked by a competitor, or a failed Series B. Conversely, a disclosed target with clean selectivity data plus a named pharma partnership would justify upgrading toward track or buy. Until those disclosures exist, the disciplined answer is to keep researching.[CV033, CV034, CV035, CV036, CV037, CV038]

8.7 Exhibits